CM Management LLC Has $1.29 Million Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)

Key Points

• CM Management LLC increased its stake in Coya Therapeutics by 25.0%, acquiring an additional 40,000 shares, and now owns approximately 1.20% of the company worth $1.29 million.
• Coya Therapeutics is now rated as a "Moderate Buy" with an average target price of $16.50, as issued by several analysts, including Chardan Capital and Lake Street Capital.
• The company's recent quarterly earnings reported an EPS of ($0.44), meeting expectations, with substantial revenue of $257.88 million, surpassing forecasts.

CM Management LLC raised its holdings in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 25.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the company's stock after purchasing an additional 40,000 shares during the quarter. CM Management LLC owned 1.20% of Coya Therapeutics worth $1,294,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of COYA. Northern Trust Corp lifted its stake in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after purchasing an additional 4,777 shares during the period. Geode Capital Management LLC boosted its position in Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock valued at $863,000 after purchasing an additional 8,267 shares during the period. XTX Topco Ltd acquired a new position in Coya Therapeutics during the 4th quarter valued at approximately $59,000. Finally, Jane Street Group LLC acquired a new position in Coya Therapeutics during the 4th quarter valued at approximately $74,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Stock Down 0.3%

COYA stock traded down $0.02 during trading on Friday, reaching $6.08. 14,985 shares of the company's stock were exchanged, compared to its average volume of 73,859. Coya Therapeutics, Inc. has a 1-year low of $4.65 and a 1-year high of $10.24. The company's fifty day moving average price is $5.93 and its 200-day moving average price is $6.07. The firm has a market cap of $101.72 million, a PE ratio of -5.68 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The firm had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, sell-side analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on COYA shares. D. Boral Capital restated a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Thursday, July 24th. Chardan Capital restated a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, July 1st. Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Lake Street Capital assumed coverage on Coya Therapeutics in a research report on Wednesday, July 9th. They set a "buy" rating and a $16.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, June 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.50.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.